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Introduction: Cell replacement therapy may be considered as an alternate approach to provide therapeutic dose
of plasma factor VIII (FVIII) in patients with hemophilia A (HA). However, immune rejection limits the use of
allogeneic cells in this mode of therapy. Here, we have examined the role of donor major histocompatibility
complex (MHC)-stimulated host CD4+CD25+ regulatory T (Treg) cells in suppressing immune responses against
allogeneic uncommitted (Lin−) bone marrow cells (BMCs) for correction of bleeding disorder in HA mice.
Methods: Allogeneic donor Lin− BMCs were co-transplanted with allo-antigen sensitized Treg cells in HA mice having
acetaminophen-induced acute liver injury. Plasma FVIII activity was determined by in vitro functional assay, and
correction of bleeding phenotype was assessed on the basis of capillary blood clotting time and tail-clip
challenge. The immunosuppression potential of the sensitized Treg cells on CD4
+ T cells was studied both in vitro
and in vivo. Suppression of inflammatory reactions in the liver against the homed donor cells by sensitized Treg
cells was analysed by histopathological scoring. Allo-specificity of sensitized Treg cells and long-term retention of
immunosuppression were examined against a third-party donor and by secondary challenge of allogeneic donor
cells, respectively. The engraftment and phenotype change of donor BMCs in the liver and their role in synthesis
of FVIII and liver regeneration were also determined.
Results: Co-transplantation of allogeneic Lin− BMCs with sensitized Treg cells led to systemic immune modulation
and suppression of inflammatory reactions in the liver, allowing better engraftment of allogeneic cells in the liver.
Allo-antigen priming led to allo-specific immune suppression even after 1 year of transplantation. Donor-derived
endothelial cells expressed FVIII in HA mice, leading to the correction of bleeding phenotype. Donor-derived
hepatocyte-like cells, which constitute the major fraction of engrafted cells, supported regeneration of the liver
after acute injury.
Conclusions: A highly proficient FVIII secreting core system can be created in regenerating liver by transplanting
allogeneic Lin− BMCs in HA mice where transplantation tolerance against donor antigens can be induced by
in vitro allo-antigen primed Treg cells. This strategy can be beneficial in treatment of genetic liver disorders for
achieving prophylactic levels of the missing proteins.* Correspondence: veenak@nii.ac.in; ashok@nii.ac.in
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Hemophilia A (HA) is an X-linked autosomal recessive
bleeding disorder in which factor VIII (FVIII) is inad-
equately synthesized. In humans, FVIII is found to be
synthesized by liver sinusoidal endothelial cells (LSECs)
[1]. Gene knockout studies have recently confirmed that
endothelial cells (ECs) are the principal source of plasma
FVIII [2, 3]. In treatment of HA, gene replacement ther-
apy showed initially encouraging results in life-long
correction of HA in animal models [4–6], although the
outcome of the phase I clinical trial was not conclusive;
there was a gradual loss of its potency because of the
formation of inhibitors [7]. As an alternative to gene
therapy, transplantation of LSECs has shown encour-
aging therapeutic benefits in HA mice [8]. Owing to a
profound shortage of transplantable donor LSECs, bone
marrow cell (BMC) therapy is considered as an alterna-
tive for these patients. Attempts have been made to cor-
rect some genetic liver diseases by transplanting BMCs,
which are capable of engrafting in the liver and replacing
the parenchyma in the regenerating liver micro-
environment and thereby produce prophylactic levels of
missing proteins [9–12]. All of the above studies were
based on transplantation of syngeneic BM-derived cells
in mice with perturbed liver in which no humoral re-
sponse to the missing proteins was observed.
Owing to intrinsic genetic defects, autologous cells
cannot be used for therapeutic correction of HA. Immu-
nosuppressants can be used to avoid rejection of donor
cells but have serious side effects on long-term adminis-
tration. CD4+ T cells of the recipient act as a double-
edged sword; they play a central role in rejection of allo-
graft and are also involved in developing peripheral
tolerance against the effector T cells. A subpopulation of
CD4+ T cells, known as regulatory T (Treg) cells, pos-
sesses immuno-modulatory properties that are capable
of establishing transplant tolerance [13]. Thus, Treg cells
are considered a good candidate to overcome the rejec-
tion of allogeneic donor cells.
In this report, we have developed allo-antigen-specific
Treg cells of recipient background, which can improve
the therapeutic benefit of allogeneic Lin− BMCs in HA
mice. This strategy facilitates allo-specific immunosup-
pression, establishes transplant tolerance, and allows
better engraftment of donor cells in the regenerating
liver. The donor-derived cells helped in regeneration of
the liver as well as in synthesis of FVIII protein that led
to bleeding phenotype correction in HA mice.
Methods
Animals
Six- to eight-week-old HA mice [B6;129S4-F8tm1Kaz/J],
C57Bl6/J, enhanced green fluorescence protein (eGFP)-ex-
pressing Bl6/J [C57Bl6/J-Tg(UBCGFP) 30Scha/J], FVB/J,eGFP-expressing FVB/J [FVB.Cg-Tg(CAGEGFP)B5Nagy/J],
and Balb/c mice were used in this study. Mice were ob-
tained from The Jackson Laboratory (Bar Harbor, ME,
USA) and maintained in individually ventilated cages and
fed with autoclaved acidified water and irradiated food ad
libitum in the experimental animal facility of the institute.
All experiments were conducted in accordance with pro-
cedures approved by the Institutional Animal Ethics Com-
mittee at the National Institute of Immunology.
Flow cytometry
Single-cell suspensions of BM, spleen, and liver were
prepared [14, 15]. Antibody staining of cells was per-
formed at 4 °C for 30 min. For biotinylated primary anti-
bodies, the washed cells were further stained with
fluorochrome-conjugated streptavidin or secondary anti-
bodies. Cells were washed in phosphate-buffered saline-
bovine serum albumin (PBS-BSA) buffer and subjected
to either analysis or sorting (FACS AriaIII; BD Pharmin-
gen, San Diego, CA, USA). The antibodies and conju-
gates used for the study were anti-CD4/biotin, anti-
CD25/PE, anti-Foxp3/AF647, Streptavidin/PerCP, and
Streptavidin/APCCy7 (all from BD Pharmingen); anti-
CD11c/PE and anti-CD44/eFluor 450 (both from
eBioscience, San Diego, CA, USA); and anti-CD31/biotin
(BioLegend, San Diego, CA, USA).
Donor antigen sensitized Treg cells and characterization
CD4+CD25+ Treg (nTreg) cells of HA mouse spleen were
co-cultured with equal number of irradiated (1200 cGy)
dendritic cells (DCs) of FVB/J mouse for 48 h. The sup-
pressive effect of Treg cells on proliferation of CD4
+ T
cells was determined by carboxyfluorescein succinimidyl
ester (CFSE) (Vybrant® CFDA Cell Tracer kit; Invitrogen,
Carlsbad, CA, USA) dilution assay, and interleukin-10
(IL-10) secretion was estimated by using enzyme-linked
immunosorbent assay (eBioscience). In T-cell suppres-
sion assay, CD4+CD25− T cells were labeled with 5 μM
CFSE by incubating for 3 min at 37 °C. DCs from FVB/J
mice (1 × 105 cells) and CFSE-labeled CD4+CD25− T
cells from HA mice (1 × 105 cells) were taken in each
well of 96-well round-bottom plate in triplicate. The
nTreg or sTreg cells were added in each well at different
ratios to T cells (0, 0.01, 0.02, 0.04, 0.1, 0.25, 0.5, and 1)
and cultured for 5 days. The dilutions of dye in viable
CFSE-labeled cells were determined by flowcytometric
analysis. Cellular viability was checked with 9 nM Sytox
Red (S34859; Molecular Probes Inc., Eugene, OR, USA).
Transplantation of cells and phenotypic correction
BM progenitor cells (Lin− BMCs) were isolated from
eGFP-expressing FVB/J and Balb/c female mice follow-
ing negative selection with MACS (Miltenyi Biotec,
Gladbach, Germany). Acute liver injury was induced by
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in male HA mice through intra-peritoneal injection.
Within 30 h of liver injury, 0.25 × 106 Lin− BMCs
(eGFP) without or with 0.25 × 105 sTreg/nTreg cells were
transplanted through tail vein injection. FVIII activity in
plasma was measured by using a Coatest SP4 FVIII kit
(Chromogenix; Instrumentation Laboratory SpA, Milan,
Italy). Correction of bleeding phenotype was assessed by
the tail-clip challenge test and whole blood clotting
time. In the tail-clip challenge test, tails were clipped at
a length of 1.5 cm without subsequent cauterization.
Mice were observed for 24 h, and percentage survival
was noted. The whole blood clotting time was deter-
mined by drawing blood into a capillary tube from the
retro-orbital plexus. The loaded capillary tube was
broken at regular intervals starting from one end and
slowly pulled apart to observe for fine strands of insol-
uble fibrin. Time taken to produce the visible clot was
recorded.
Liver histopathology
Liver tissues were fixed in 10 % buffered formalin. Paraf-
fin sections were stained with hematoxylin and eosin.
Histopathological abnormalities in the liver tissue sec-
tions were scored in accordance with a published proto-
col [16]. Histopathological scoring of inflammatory
reactions are included in Additional file 1: Table S1.
Immunostaining of cells/tissues
Four percent paraformaldehyde-fixed cells were cytos-
pined on poly-L-Lysine-coated glass slides. Liver tissue
was frozen in tissue freezing medium (Jung; Leica Micro-
systems, Wetzlar, Germany), and 5-μm sections were cut.
The cells or tissue sections were permeabilised with 0.1 %
saponin in PBS for 30 min and then blocked with 3 %
BSA solution for 1 h. Samples were stained with pri-
mary antibodies overnight at 4 °C, washed, and further
stained with Alexafluor-conjugated secondary anti-
bodies (Molecular Probes Inc.) at room temperature for
1 h. Washed cells/sections were briefly treated with
4′,6-diamidino-2-phenylindole (DAPI) (10 μg/ml) and
mounted on glass slides by using ProLongR anti-fade
(Molecular Probes Inc.). Antibodies used for immuno-
staining were anti-GFP (Clontech-Takara Bio Company,
Kyoto, Japan), anti-CD31 biotinylated (BioLegend) anti-
FVIII(lc) (Santa Cruz Biotechnology Inc., Dallas, TX,
USA), anti-albumin (Bethyl Laboratories Montgomery,
TX, USA), and anti-Foxp3 and anti-F4/80 (eBioscience).
Foxp3 staining was performed following DAB-HRP (3,
3′-diaminobenzidine-horseradish peroxidase) method
(Vector Laboratories, Burlingame, CA, USA). The stained
sections or cells were observed under an Olympus fluores-
cence microscope, and images were acquired by DP70
digital camera (Model IX51; Olympus, Tokyo, Japan)using LCPlanFl 20× and 60× objectives and Image Pro
software (Media Cybernetics, Inc., Rockville, MD, USA).
High-magnification images were taken with a Zeiss LSM
510 META confocal laser-scanning microscope (Carl
Zeiss, Oberkochen, Germany) using a Plan-Apochromat
63×/1.4 oil objective with LSM 510 software for image ac-
quisition and Zeiss LSM Image browser version 4.2.0.121
for processing. Relative cell fluorescence was measured by
using ImageJ software (National Institutes of Health,
Bethesda, MD, USA).
Low-density lipoprotein uptake assay
Low-density lipoprotein (LDL) uptake by ECs was
assessed by fluorescence microscopy after incubation of
the cells with 10 μg/ml acetylated LDL labeled with
1,19-dioctadecyl-3,3,39,39-tetramethylindo-carbocyanine
perchlorate (DiI-Ac-LDL) (Molecular Probes Inc.) for
2 h at 37 °C.
Gene expression
Total RNA was isolated from purified cellular fractions
by using TRI Reagent (Invitrogen), and cDNA was
synthesized by using a High Capacity cDNA Reverse
Transcription Kit (Applied Biosystems, part of Thermo
Fisher Scientific Inc., Waltham, MA, USA). Real-time
PCR was performed by using SYBR green technology
(Applied Biosystems) in a Stratagene Mx3000P QPCR
System (Agilent, Santa Clara, CA, USA). The primers used
for the PCR are Gapdh (forward primer: 5′-ACGGCCG
CATCTTCTTGTGCA-3′, reverse primer: 5′-CAGGCGC
CCAATACGGCCAA-3′) and FVIII (forward primer: 5′-
GCCTGGGCTTA TTTCTC TGATG-3′, reverse primer:
5′-TGAGCAGGATTCAGTGTGTTCG-3′).
Statistics
Results of multiple experiments were reported as mean ±
standard error of the mean. Student’s t test was carried
out to calculate the significance between the means of
both groups, and a P value of less than 0.05 was con-
sidered significant. All analyses were carried out by
using GraphPad Prism software, version 5.02 (GraphPad
Software, Inc., La Jolla, CA, USA).
Results
Allogeneic Lin− BMCs protect HA mice from bleeding
challenge in the presence of sTreg cells
Transplantation of allogeneic Lin− BMCs (FVB/J) and
sTreg cells was performed in HA mice as in the scheme
in Fig. 1a after inducing acute centrilobular necrosis in
the liver, as presented in Additional file 2: Figure S1.
Phenotype correction of the recipient mice was assessed
after 3 months of transplantation. The HA mice used in
the study contain neo sequence in the exon 16 of factor
VIII A3 domain, so intact FVIII (lc) protein is not
Fig. 1 Co-transplantation of sTreg cells and Lin
− BMCs facilitates therapeutic correction in HA mice. a Scheme of the experiment. Lin− BMCs
(0.25 × 106 cells) from female FVB-GFP mice (H2Kq) were transplanted into HA mice (H2Kb) through the tail vein within 30 h of acute liver injury,
and the recipient mice were grouped as HAT-A. The Treg cells from HA mice were primed against donor MHC antigens by co-culturing with
splenic DCs of FVB mice for 48 h to generate allo-antigen sensitized Treg cells (sTreg cells). To establish transplant tolerance, allogeneic Lin
− BMCs
and sTreg cells were co-transplanted into HA mice, and the recipient mice were grouped as HAT-AT. b Plasma FVIII activity was measured by
in vitro coagulation assay performed by using a Coatest assay kit. FVIII activity as percentage of normal plasma in wild-type mice is shown. There
was no significant increase in FVIII activity in HAT-A mice but the activity was much higher in HAT-AT mice (P < 0.0001, HAT-A versus HAT-AT
mice) after 3 and 6 months of transplantation. c Capillary blood clotting time. WT, HA, HAT-A, and HAT-AT mice were subjected to the assay after
3 months of transplantation. d Tail-clip challenge test. Survival of mice after 24 h of tail clip was determined, and HAT-AT group showed no mortality.
BM bone marrow, BMC bone marrow cell, DC dendritic cell, FVIII K/O factor VIII knockout, HA hemophilia A, HAT-A hemophilia A mice transplanted with
allogeneic cells, HAT-AT hemophilia A mice transplanted with allogeneic and regulatory T cells, n number of mice in each experiment, sTreg sensitized
regulatory T, WT wild-type
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and HAT-A mice after 3 and 6 months of transplant-
ation was determined by Coatest assay. The activity in
HAT-A mice was marginally improved to 2.9 ± 0.6 %,
whereas a significant increase up to 16.1 ± 2.2 % of wild-
type activity was obtained in HAT-AT mice (Fig. 1b).
The plasma FVIII activity was retained even after
6 months of transplantation. The capillary blood clotting
time in HAT-A mice was marginally decreased, whereassignificant (P < 0.0001) reduction (2.9 ± 0.9 against 12.9
± 0.9 min) was observed in the HAT-AT group as com-
pared to HA mice (Fig. 1c). All 18 hemophilic mice that
received allogeneic Lin− BMCs with sTreg cells (HAT-
AT) achieved hemostasis after the tail-clip challenge. In
the HAT-A group, most of the mice died because of ex-
cessive bleeding within 24 h of the tail-clip, as did HA
mice (Fig. 1d). Phenotype correction in the HAT-AT
group implies adequate FVIII production in HAT-AT
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compared to HAT-A and HA mice.sTreg cells exhibit enhanced regulatory effects than
nTreg cells on T cell proliferation in vitro
In the above experiments, sTreg cells were used because of
robust regulatory properties as compared to nTreg cells.
To know which of the two regulatory cell types was more
potent, we conducted T-cell suppression assay. Splenic
CD4+CD25+ Treg cells of HA mice were sensitized to allo-
DCs as before, and a proliferation assay was conducted by
co-culturing CFSE-labeled T cells with different propor-
tions of sensitized (sTreg) and naïve (nTreg) cells. The re-
sults showed a dose-dependent inhibition of T-cell
proliferation by both regulatory cell types. The suppressive
effect was pronounced (P < 0.001, 0.05) with sTreg cells at
ratios of 0.1:1 up to 1:1 to T cells when compared to nTreg
cells (Fig. 2a, b). There was no significant change in Foxp3
expression in the Treg cells on antigen priming, and more
than 90 % of the cells expressed the marker as in nTreg
cells, depicted in the dot-plots of Additional file 3: Figure
S2.
As Treg cells also suppress proliferation of immune re-
active T cells by secretion of cytokines like IL-10 and
transforming growth factor-beta, we determined IL-10
level in the culture supernatants of the above experi-
ments. Interestingly, both nTreg and sTreg cells secreted
IL-10, but the quantity was significantly higher in sTreg
cells as compared to nTreg cells (Fig. 2c). Hence, the
above results suggest that priming of Treg cells with
major histocompatibility complex (MHC) antigen of
allogeneic DCs enhances their prospective regulatory ef-
fects on T cells during subsequent exposure of the same
antigen.Allo-specific systemic immune modulation by sTreg cells
in HAT-AT mice
Time course analysis of CD4+CD25+Foxp3+ Treg cells in
the spleen of HAT-AT and HA-SC (sham control mice
in which liver was damaged but neither Lin− BMCs nor
sTreg cells were transplanted) mice showed a significant
increase in the percentage of Treg cells in the HAT-AT
group in comparison to the HAT-SC group of mice
within the first 2 months of transplantation, and the
percentages later became comparable (Fig. 3a). Further-
more, the percentage of splenic CD4+ T cells in HAT-A
mice was 31.9 ± 3.62 %, which significantly (P < 0.01)
decreased to 17.13 ± 1.15 % in HAT-AT within 10 days
of co-transplantation with sTreg cells. Interestingly, this
suppressive effect was continued throughout the course
of the study (Fig. 3b). The above results suggest that
effective immune suppression and development of toler-
ance are attributed to sTreg cells.To determine in vivo allo-specificity of sTreg cells, an
experiment was set up to compare CD4+ T-cell activa-
tion by allogeneic donor Lin− BMCs from two different
donor backgrounds (Balb/c and FVB/J) in the presence
of FVB-specific sTreg cells. After 2 days of transplant-
ation, the levels of antigen-experienced CD4+CD44+ ac-
tivated T cells in the spleen were analysed, and the basal
level in the spleen of normal mice was 0.95 ± 0.07 %
(data not shown). We observed a significant (P < 0.05)
reduction of activated CD4+CD44+ T cells in the case of
HAT-AT (FVB/J donor) as compared to HAT-A (FVB/J
donor). In the parallel experiments, the suppression of
T-cell activation against Lin− BMCs from Balb/c mice
(third-party donor) was insignificant (P = 0.44) in the
presence of FVB-specific sTreg cells. There was a
significant reduction in the levels of CD4+CD44+ T cells
in HAT-AT mice (FVB/J donor) when compared with
HAT-AT mice (Balb/c donor) in the presence of FVB-
specific sTreg cells (Fig. 3c). These results indicate that
sTreg cells exhibit allo-specificity in vivo.
sTreg cells suppress immune reactions in recipient liver
Examination of gross abnormalities in the liver, spleen,
kidney, and lymph nodes of HAT-A and HAT-AT mice
showed that inflammatory responses were largely exhib-
ited only in the HAT-A group (Fig. 4a, b). The immune
response against allograft can lead to infiltration of T
cells into the graft site (in this case, the liver) and this
may lead to persistent inflammatory reactions [18] that
can result in cellular rejection. The extent of inflamma-
tory response in the liver was ascertained by scoring
various parameters [16] observed in HAT-A and HAT-
AT mice (Fig. 4c and histopathological scorings men-
tioned in Additional file 1: Table S1) at various time
intervals after transplantation. Among these, bile duct
inflammation was rarely observed in our study. Histo-
pathological scoring showed a significant decline of
inflammatory reactions in the HAT-AT group when
compared to the HAT-A group (Fig. 4d). These prelim-
inary results indicate that sTreg cells can circumvent in-
flammatory responses in the target site of engraftment,
such as the liver in this case.
As migration of Treg cells to the site of engraftment
can confer protection to allograft against cytotoxic ef-
fects of infiltrating T cells, we examined their presence
in different liver lobes. Morphometric analyses confirmed
the presence of an average of six Foxp3+ cells per field in
HAT-AT mice liver sections and this was significantly
(P < 0.0001) higher than that in HAT-A mice (Fig. 5a).
To determine the long-term immune suppression by
sTreg cells, after 1 year of transplantation, HAT-A and
HAT-AT mice were given a second dose of 0.25 × 106
Lin− BMCs (FVB/J donor) after liver injury was induced.
An intense inflammatory response was evidenced in the
Fig. 2 (See legend on next page.)
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Fig. 2 In vitro functional characterization of sTreg cells. a T-cell suppression (CFSE dilution) assay. DCs (1 × 10
5 cells) of FVB/J mice and 1 × 105
CFSE-labeled CD4+CD25− T cells (HA mice) were added to set up T-cell suppression assay. The nTreg or sTreg cells were added in each well at
different ratios of T cells and cultured for 5 days. The proliferation of T cells in mixed lymphocyte reaction was measured in terms of dilution of
CFSE intensity as shown in the representative histograms. b A significant (*P = 0.0142) difference in suppression of T-cell proliferation between
two groups of Treg cells was noticed at 0.1:1, 0.25:1, 0.5:1, and 1:1 ratios of the regulatory to effector T cells. c IL-10 secretion in the culture super-
natants (Treg cells: T cells = 1:1) was measured by enzyme-linked immunosorbent assay. A significant increase in IL-10 levels was observed in
cultures with sTreg cells (P = 0.04). CFSE carboxyfluorescein succinimidyl ester, DC dendritic cell, HA hemophilia A, IL-10 interleukin-10, n number of
experiments, nTreg naïve regulatory T, sTreg sensitized regulatory T, Treg regulatory T (***) P < 0.0001, (*) P < 0.05
Kochat et al. Stem Cell Research & Therapy  (2015) 6:129 Page 7 of 16liver of HAT-A mice as compared to HAT-AT mice as
shown in Fig. 5b (P = 0.05). The inflammatory score in
HAT-AT mice after secondary challenge with allogeneic
cells (Fig. 5b) was much higher than that observed in
the earlier experiment (Fig. 4d) because of aging of mice
and inflicting second time injury. These results indicate
that immune suppression in the liver by sTreg cells can
reduce the cellular responses involved in graft rejection
even over a period of 1 year.
Donor-derived endothelial cells are the major contributor
of FVIII in HAT-AT mice
Among the non-parenchymal cells, Lin− BMCs were
found to generate mainly CD31-expressing ECs (Fig. 6a).
A few F4/80-expressing Kupffer cells (KCs) were also de-
tected in the recipient liver (Fig. 6b). Earlier, it has been
shown that in liver FVIII is synthesized primarily by
LSECs but that a small amount can be synthesized by
KCs. The contribution of donor cells to LSEC and KC
fractions in HAT-AT mice liver was ascertained by flow
cytometric analysis. It was revealed that GFP+ donor
cells constituted 2.6 ± 0.64 % of total non-parenchymal
fraction, of which 2.02 ± 0.42 % was CD31+ ECs and
0.37 ± 0.02 % was F4/80+ macrophages/KCs (Fig. 6c).
The time course analysis indicated that there was an in-
crease of GFP+CD31+ ECs in the non-parenchymal frac-
tion of the liver after initial engraftment; this is
presented in the dot-plot analysis in Additional file 4:
Figure S3. Further analysis of Ki67 antigen revealed that
these donor-derived ECs also underwent proliferation
along with host ECs. The percentages of proliferation of
host and donor-derived ECs are shown in Additional file
5: Figure S4.
After 3 months of transplantation, FVIII expression in
the liver of HAT-AT mice was analysed. The HA mice
used in the study had a neo sequence in the exon 16 of
factor VIII A3 domain preventing the synthesis of FVIII
light chain (lc) protein and so primers were specifically
designed against this region. Thus, amplification did not
occur in HA mice samples, whereas FVIII(lc) expression
was observed in wild-type and HAT-AT liver samples
(Fig. 6d).
To decipher the role of donor-derived cells in correc-
tion of HA, we first analysed relative FVIII transcriptlevels in few specific liver non-parenchyma as well as
BMC fractions of wild-type mice with respect to donor
Lin− BMCs. Among all of the cell types analysed, LSECs
apparently expressed the highest level of FVIII(lc) tran-
script, followed by KCs, CD45− (stromal cells), and
CD11b+ BMCs; relative fold changes of gene expression
are depicted in Additional file 6: Figure S5. Next, BM-
derived cells (GFP+CD31+ and GFP+F4/80+) were iso-
lated from the liver of HAT-AT mice and immunocyto-
chemically analysed for the expression of FVIII(lc)
protein. As shown in Fig. 6e, LSECs isolated from HA
mice did not express FVIII(lc) protein, whereas wild-
type LSECs and ECs isolated from HAT-AT mice ex-
press the same. A similar trend was observed in wild-
type KCs and eGFP+F4/80+ cells, isolated from HAT-AT
mice liver, but the expression level was much lower. To
compare FVIII(lc) protein expression in liver resident
LSECs and KCs (in wild-type mice) with BM-derived
ECs and KCs (in HAT-AT mice), we have determined
relative fluorescence intensity of the protein by ImageJ
software. It was apparent that FVIII(lc) protein level was
significantly high in both LSECs and BM-derived ECs
but much lower in KCs (Fig. 6e, bar diagram). On the
basis of above results, we propose that BM-endothelial
progenitor cells were converted into FVIII-expressing
LSEC-like cells in the recipient mice liver. To prove that
LSECs and BM-derived ECs were functionally similar,
we conducted an LDL uptake study; the results revealed
that LDL uptake was comparable, as presented in
Additional file 7: Figure S6. To confirm that engrafted
BM-derived ECs in liver synthesized FVIII, we conducted
immunohistochemistry analysis in HAT-AT liver sections
after 4 months of transplantation. The results clearly dem-
onstrate that GFP+CD31+ cells expressed FVIII (Fig. 6f).
These results suggest that transplantation of Lin− BMCs
causes phenotype correction in HA mice because of the
synthesis of FVIII by BM-derived ECs.
sTreg cells support allogeneic BMC-mediated liver
regeneration and functional improvement
Transplant tolerance generated by sTreg cells can im-
prove engraftment of donor cells in the liver. So liver
sections of HAT-A and HAT-AT mice were analysed
for engraftment of eGFP-expressing donor cells after
Fig. 3 sTreg cells modulate systemic immune response with allo-specificity in vivo. a Time course analysis of Treg cells by flow cytometry in both
HAT-AT and HA-SC mice. Representative dot-plots are shown in the left panel, and statistical analysis in the right panel. b CD4+ T cells in spleen of
HAT-AT and HAT-A mice were analysed by flow cytometry. Representative dot-plots are shown in the left panel, and statistical analysis in the right
panel. c Allo-specific activation of sTreg cells. T-cell activation in response to allogeneic Lin
− BMCs of FVB-GFP and Balb/c mice were compared.
Representative dot-plots show the levels of CD4+CD44+ T cells after 48 h of transplantation (left panel), and statistical analysis is shown in the right
panel (n = 3). *P < 0.05, **P < 0.01. BMC bone marrow cell, HA-SC sham control mice in which liver was damaged but neither Lin− bone marrow
cells nor sensitized regulatory T cells were transplanted, HAT-A hemophilia A mice transplanted with allogeneic cells, HAT-AT hemophilia A mice
transplanted with allogeneic and regulatory T cells, n number of mice in each experiment, nTreg naïve regulatory T, sTreg sensitized regulatory T,
Treg regulatory T
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Fig. 4 Sensitized regulatory T cells induce suppression of inflammatory responses in the liver. a Splenomagaly in HAT-A (1) mice in comparison
with HAT-AT (2) and HA (3) mice. b Gross macroscopic abnormalities in mice. Mice with anomalies in various organs were counted, and percentage of
mice with each anomaly was calculated. Most of the HAT-A mice showed abnormalities with respect to two to three indicators, whereas more
than 90 % of the HAT-AT mice were normal. c Inflammation in the liver by histopathological analysis of HAT-A and HAT-AT mice after 120 days
of transplantation. Representative images are shown for scoring of various inflammatory parameters: (1) portal inflammation, (2) periportal
necro-inflammation, (3) endotheliasis, (4) necrosis, (5) sinusoidal lymphocyte infiltration, and (6) lobular necro-inflammation. Arrow indicated different
immunoreactions with respect to the said parameters (scale of 100 μm; 200× magnification). d Comparative inflammatory scoring on the basis of
histopathological analysis of the liver at different time intervals after transplantation in HAT-A and HAT-AT groups (*P< 0.05, **P < 0.01). HAT-A hemophilia
A mice transplanted with allogeneic cells, HAT-AT hemophilia A mice transplanted with allogeneic and regulatory T cells, n number of mice in
each time point
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Fig. 5 Long-term retention of transplant tolerance. a Migration of regulatory T cells to the liver. Representative photomicrographs show Foxp3-expressing
cells (left panel, arrows) after 3 months of transplantation (scale of 100 μm; 400× magnification). Statistical analysis is shown in the right panel. b After 1 year
of primary transplantation, a second dose of allogeneic 0.25 × 106 Lin− BMCs from FVB-GFP cells was given to HAT-A and HAT-AT mice after liver injury
was inflicted. Representative photomicrographs show extensive immune reactions in HAT-A mice (scale of 100 μm; 200× magnification). Statistical
analysis of inflammatory scores determined on the basis of histo-pathological analysis of liver is shown in the right panel. BMC bone marrow cell, HAT-A
hemophilia A mice transplanted with allogeneic cells, HAT-AT hemophilia A mice transplanted with allogeneic and regulatory T cells, n number of mice
in each experiment (***) P < 0.0001, (*) P < 0.05
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analysis of recipient liver sections showed that, owing
to suppression of immune response, engraftment of
more allogeneic BMCs occurred in HAT-AT mice liver
as compared to HAT-A (Fig. 7a). Morphometric ana-
lysis based on 30 non-overlapping fields in each set of
mice showed that the percentage of GFP+ cells in
HAT-AT liver was 7.27 ± 0.82 %, which is significantly
higher (P < 0.0001) than that in HAT-A liver (Fig. 7a,
bar diagram). On further analysis, it was found that many
donor-derived cells expressed albumin and attained
morphology similar to that of hepatocytes (Fig. 7b). Mor-
phometric analyses of images (200× magnification) in 20
different fields of liver sections per mouse after 45 and
120 days of transplantation showed that 5.26 ± 0.88 % and
7.57 ± 0.47 % cells, respectively, were eGFP-expressing.
The percentages of donor-derived albumin-expressing
cells in these two time points were 4.72 ± 0.87 % and
5.72 ± 0.5 %, respectively (Fig. 7c, bar diagram).
Since donor-derived cells increased in their number,
we were interested to know how long they can multiply.
So liver sections were co-stained for eGFP and Ki67 anti-
gens after 45 and 120 days of transplantation. It was re-
vealed that some donor-derived cells that morphologically
resembled hepatocytes underwent proliferation in the
45th day samples, but no Ki67 staining was observed inthe liver after 120 days of transplantation (Fig. 7d). As the
donor-derived hepatocytes stopped proliferation in a later
time point, we concluded that liver regeneration was
completed.
Acute liver injury due to administration of toxic doses
of acetaminophen results in increased serum alanine
aminotransferase (ALT) and aspartate aminotransferase
(AST) levels. These serum parameters were gradually
normalized during liver regeneration. Owing to persist-
ent inflammatory reactions for chronic rejection, the
serum AST and ALT levels were maintained significantly
high in HAT-A mice even after 90 days of transplant-
ation. As expected, they decreased to normal levels in
HAT-AT mice by this period (Fig. 7e, f ).
Discussion
In developed countries, factor replacement therapy is
readily available, but owing to high prophylactic treat-
ment cost, many patients are still treated on demand.
The patients in the developing countries, owing to ex-
treme financial constraint, are treated mostly on demand
[19]. So a permanent solution for HA has been sought
for quite some time. Gene therapy appears to be promis-
ing as a small increase in plasma factor levels can essen-
tially improve the clinical outcome of HA [20]. Clinical
studies have shown that 10–40 % of patients with the
Fig. 6 (See legend on next page.)
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Fig. 6 FVIII synthesis by donor-derived endothelial cells and Kupffer cells in HAT-AT liver. a Donor-derived endothelial cells indicated by white arrow
(anti-GFP/donkey anti-mouse Alexa fluor 488 and anti-CD31/donkey anti-rat Alexa fluor 594) in HAT-AT liver (scale of 10 μm; 630 × 2.8 zoomed
magnification). b Donor-derived Kupffer cells indicated by white arrow (anti-GFP/donkey anti-mouse Alexa fluor 488 and anti-F4/80/donkey
anti-rat Alexa fluor 594) in HAT-AT liver (scale of 10 μm; 630 × 2.8 zoomed magnification). c Flow cytometric analysis of donor cells in non-parenchymal
fraction of HAT-AT mouse liver after 1 month of transplantation. Representative dot-plots are given in the left panel, and quantitative analysis is shown
in the right panel (n = 3). d FVIII(lc) gene expression in livers of HAT-AT, HA, and WT mice. e Immunocytochemical analysis of FVIII in endothelial and
Kupffer cells from HA, WT, and HAT-AT mice (scale of 100 μm; 600× magnification). Relative cell fluorescence intensities are shown in the bar diagram
on right. f Highly magnified confocal images (scale of 10 μm; 630× 2.8 zoomed magnification) show that donor-derived endothelial cells express
FVIII indicated by white arrow (anti-GFP/donkey anti-mouse Alexafluor 488, anti-CD31/donkey anti-rat Alexafluor 594, anti-FVIII(lc)/donkey anti-rabbit
Alexafluor 647). BMD bone marrow derived, DAPI 4′,6-diamidino-2-phenylindole, EC endothelial cell, GFP green fluorescent protein, FVIII factor VIII,
FVIII(lc) factor VIII light chain, HA hemophilia A, HAT-AT hemophilia A mice transplanted with allogeneic and regulatory T cells, KC Kupffer cell, n number
of mice in each experiment, NPC non-parenchymal cell, WT wild-type
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fails in the long run [21]. In humans, the primary source
of plasma FVIII is LSECs [1–3]; however, the same has
been found to be synthesized in low quantities by mesen-
chymal stem cells (MSCs) [22, 23] and macrophages [23].
Various cell-based therapies have been advocated for
the treatment of HA in experimental animals, and in all
cases therapeutic correction levels of plasma FVIII were
achieved. Previously, we showed that syngeneic BM-
derived uncommitted cells can synthesize FVIII and
confer protection against bleeding to death [12, 24].
Here, we have identified three different cell types—ECs,
KCs, and hepatocytes—that can originate from allogen-
eic Lin− BM-derived cells in recipient mouse liver. Inter-
estingly, we observed that FVIII synthesis occurred
primarily in BM-derived ECs. Owing to the shortage of
cadaver livers, therapeutic correction of HA by transfer-
ring healthy LSECs [8] may not be feasible. Lin− BMCs
contain endothelial progenitors [25, 26]; so we propose
that these can ultimately differentiate into functional
LSECs [27] and produce FVIII. Lin− BMCs also consist
of MSCs, which can participate directly in liver regener-
ation by secreting factors that help in tissue repair,
modulation of inflammatory responses, and activation of
hepatic progenitor cells [28]. An earlier report suggested
that BM-MSCs and mononuclear cells in peripheral
blood secrete FVIII and can act as a supporting system
to deliver FVIII at the bleeding sites [23]. Even though
MSCs can express FVIII protein [22], they have been
used for short-term transplantation study of phenotype
conversion in HA mice [23].
Our study confirmed the majority of BM-derived cells
as hepatocyte-like cells, as a substantial fraction of
necrosed hepatocytes were replaced by them [12]. Even
though BM-derived hepatocytes have been reported in
liver regeneration [12, 29, 30], the plasticity of BM stem
cells had been questioned by many groups. The general
belief is that cell fusion is the principal mechanism for
generation of BM-derived hepatocytes [31–34]. Even if
BMCs assume hepatic phenotype by fusion followed by
ploidy reduction or by direct differentiation, ourapproach still has a high clinical relevance in the context
of liver regeneration using allogeneic BMCs. In
acetaminophen-induced liver injury, we observed that
donor cells were engrafted mostly in the liver rather
than in the BM or spleen (~0.1 %). In contrast, in the
case of a radiation-induced injury model, substantial
fractions of BMCs are found to be engrafted in the BM
and spleen because of their natural niches. Thus, we
conclude that Lin− BMCs may act as an ideal source of
cells for liver regeneration in HA mice.
A highly competent core system involving FVIII-
expressing LSECs is more desirable so that repeated in-
fusion of purified FVIII will not be required. Moreover,
since liver is an immune-privileged organ, the engrafted
Lin− BMCs can facilitate long-term management of the
disease. In the present model, transplantation of Lin−
BMCs into HA mice restored plasma FVIII activity well
above the therapeutic correction level (≤10 % normal ac-
tivity). Another unique advantage was that no FVIII in-
hibitor was detected in our earlier study using the same
cells but from a syngeneic source [12]. Anti-FVIII anti-
body (inhibitor) formation in the long run occurs both
in cases of recombinant and plasma-derived FVIII ther-
apy and in the experimental FVIII gene therapy model
[7], which urged for alternate immunological approaches
to prevent these humoral responses [35–37]. We propose
that in perturbed liver a fraction of the damaged hepato-
cytes, LSECs, and KCs are replaced by BM-derived cells.
High expression of FVIII by BM-derived ECs suggests that
endothelial progenitor cells of the BM might have differ-
entiated into liver-specific endothelial-like cells. We ob-
served relatively high expression of FVIII by these cells as
compared with wild-type LSECs and this may be due to
high selection pressure in HA mice for the synthesis of
FVIII. This could explain why plasma FVIII activity in
HAT-AT mice was not commensurate with the number of
BM-derived ECs engrafted in the liver.
As hemophilia is a genetic disease, autologous cells
cannot be used for treatment unless they are genetically
modified to express the desired protein. After allogeneic
transplantation, the host T lymphocytes upon activation
Fig. 7 Engraftment and regeneration of liver by donor-derived hepatocytes. a Representative photomicrographs show immunohistochemistry
analysis of liver sections of HAT-A and HAT-AT mice after 4 months of transplantation. Sections were stained with anti-GFP/donkey anti-mouse
Alexafluor 488 (scale of 100 μm; 200× magnification). Statistical analysis of GFP+ cells (indicated by white arrow) is shown in the right panel.
b Immunohistochemical analysis of HAT-AT mouse liver sections after 4 months of transplantation. Representative images (scale of 20 μm; 630×
magnification) show donor derived hepatocytes (anti-GFP/donkey anti-mouse Alexa fluor 488 and anti-albumin/donkey anti-goat Alexa fluor
594). c Quantitative analysis of GFP+ and GFP+albumin+ cells in HAT-AT liver (200× magnification) after 45 and 120 days of transplantation
(*P = 0.03). d Representative images for Ki67+ donor cells in HAT-AT liver after 45 and 120 days of transplantation (scale of 10, 20 μm; 630 × 2.8
magnification). e Analysis of serum AST levels in HAT-AT and HAT-A mice after 45 and 90 days of transplantation. f Analysis of serum ALT levels
in HAT-AT and HAT-A mice after 45 and 90 days of transplantation. ALB albumin, ALT alanine aminotransferase, AST aspartate aminotransferase,
GFP green fluorescent protein, HAT-A hemophilia A mice transplanted with allogeneic cells, HAT-AT hemophilia A mice transplanted with allogeneic
and regulatory T cells, IU international units, n number of mice in each experiment (***) P < 0.0001, (*) P < 0.05
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troy the donor cells as was evidenced by low retention
of donor cells in HAT-A mice. Allo-graft rejection is
mediated by three effector pathways: (a) delayed-type
hypersensitivity (DTH) reactions by allo-antigen activated
CD4+ T cells, (b) activation of CD8+ cytotoxic T lympho-
cytes, and (c) antibody-mediated. Since the liver is themajor site for engraftment of the allogeneic Lin− BMCs,
inflammatory reactions were pronounced in the liver. The
T-cell response was evidenced by low retention of donor
cells in HAT-A mice. In this study, we examined the re-
sponse of CD4+ T cells to MHC antigens on allogeneic
donor cells and their suppression by establishing periph-
eral tolerance using Treg cells. We have demonstrated that
Kochat et al. Stem Cell Research & Therapy  (2015) 6:129 Page 14 of 16sTreg cells can suppress immune responses against allo-
geneic BMCs by reducing inflammatory response in the
liver, thus leading to better engraftment of cells. Our find-
ing concurred with other reports in which allo-antigen-
specific Treg cells improved peripheral tolerance to BM,
skin, and cardiac allo-grafts [38, 39].
During sensitization, Treg cells were primed against
MHC molecules of the donor cells. In the host, these sTreg
cells, through linked suppression, not only recognize a
single allo-antigen exposed during in vitro sensitization
but also can suppress immune responses against most
allo-antigens expressed by the graft [40]. These activated
Treg cells in circulation can also induce secondary regula-
tory phenotype in circulatory T cells by infectious toler-
ance and generate induced Treg cells, which can further
lead to effective immune suppression during the rejection
phase [41]. Furthermore, we conclude that contact-
independent mechanisms were also responsible for con-
trolling immune response as IL-10 was detected in T-cell
proliferation assay [42, 43]. Another benefit of adoptive
transfer of in vitro antigen primed Treg cells was that their
suppressive effects were comparatively antigen-specific as
no significant activation of CD4+ T cells was observed
when sTreg cells were co-transplanted with third-party
donor Lin− BMCs. Not only that, our preliminary results
suggested retention of peripheral tolerance for long dur-
ation with a single dose of sTreg cells. The presence of sig-
nificantly higher numbers of Treg cells in recipient liver
proved that either sTreg cells or induced Treg cells, derived
from T-cell pool, or both can migrate to the primary site
of inflammation to prevent rejection of allogeneic cells.
Long-term management of HA by the synthesis of
prophylactic levels of FVIII by donor-derived cells can
overcome the requirement for repeated infusion of FVIII
in clinical settings. Furthermore, this approach will allow
us to overcome biosafety issues pertaining to gene therapy.
In future adoptive transfer of donor MHC, primed Treg
cells may substitute for the use of immunosuppressive
drugs in case of transplantation of allogeneic cells. If the
present approach has to be experimented in higher animal
models of HA like Chapel Hill dogs, a pre-conditioning
regimen of FVIII is recommended to protect the recipient
against initial hemorrhage while inducing partial liver in-
jury. Our preliminary results suggests that Treg cells can be
taken from the recipient and primed against donor anti-
gens and expanded in vitro to obtain enough cells for
exerting immune suppressive effects. Besides establishing a
pre-conditioning FVIII regimen, further studies need to be
pursued on long-term retention of allo-specificity of these
primed Treg cells before bench-to-bedside translation.
Conclusions
Our report establishes that transfer of allo-antigen primed
Treg cells along with allogeneic Lin
− BMCs in a liverregeneration model of HA mice allows engraftment of
BM-derived endothelial progenitor cells in liver, synthesis
of FVIII by donor-derived cells, and subsequent correction
of bleeding phenotype. Engraftment of allogeneic cells in
the liver was possible because of systemic immune sup-
pression and reduction in inflammatory reactions in the
liver, the latter of which promotes generation of allo-
antigen-specific transplantation tolerance. Furthermore,
donor BM-derived hepatocytes play an important role in
regeneration of injured liver parenchyma.
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